SCHEMBL1719666

SCHEMBL1719666

CN(C)Cc1nsc2[nH]c(=O)c3ccccc3c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.54
POLB P06746 1/20 0.51
PIM1 P11309 3/20 0.42
PIM2 Q9P1W9 3/20 0.42
TNKS O95271 6/20 0.39
PARP15 Q460N3 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
PIM3 Q86V86 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4A O75164 1/20 0.36
KDM4B O94953 1/20 0.36
KDM5C P41229 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721012 0.83 PIM1 (0.46) PARP1POLBPIM1PIM2PIM3
SCHEMBL1719946 0.83 PARP1 (0.41) PARP1POLBPIM1PIM2TNKS
SCHEMBL1720496 0.76 PARP1 (0.45) PARP1TNKSPARP15TNKS2PIM3
SCHEMBL1719983 0.75 PARP1 (0.39) PARP1TNKSPARP15TNKS2KMT2A
SCHEMBL7980353 0.72 PARP1 (0.54) PARP1POLBPIM1PIM2TNKS
SCHEMBL1719888 0.72 POLB (0.51) PARP1POLBPIM1PIM2TNKS
SCHEMBL424273 0.71 PARP1 (0.97) PARP1POLBPIM1PIM2TNKS
SCHEMBL1720121 0.71 PARP1 (0.53) PARP1POLBPIM1PIM2TNKS
Hydrochloric Acid SCHEMBL4320664 0.71 PARP1 (0.56) PARP1POLBPIM1PIM2TNKS
Hydrochloric Acid SCHEMBL4326979 0.70 PARP1 (1.00) PARP1POLBPIM1PIM2TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885POLB 42/4885PIM1 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.